Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAGNESIUM SULFATE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Prevention and treatment of seizures in preeclampsia and eclampsia,Treatment of hypomagnesemia,Treatment of acute asthma exacerbations (off-label),Tocolysis to delay preterm labor (off-label),Treatment of torsade de pointes (off-label)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Magnesium sulfate is not metabolized. It is primarily excreted unchanged by the kidneys via glomerular filtration.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Approximately 30-35%, primarily to albumin
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
0.5-0.7 L/kg; distributes primarily to extracellular fluid, with lower penetration into cells and CSF
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100%; intramuscular: approximately 80-90%; oral: 10-30% due to limited gastrointestinal absorption and osmotic effects
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
GFR <20 m L/min: Use with extreme caution; reduce dose by 50% and monitor serum magnesium levels. GFR 20-50 m L/min: Reduce dose by 25-50%. Avoid if anuric.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific Child-Pugh based adjustments; however, caution in severe hepatic impairment due to risk of hypotension and CNS depression.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Neonates (seizures): IV 0.2-0.4 m L/kg of 50% solution (100-200 mg/kg) over 5-10 minutes; may repeat once. Children: 0.2-0.4 m L/kg IV/IM (as 50% solution) for hypomagnesemia; maximum single dose 8 g.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Start at low end of dosing range due to age-related renal function decline; frequent monitoring of serum magnesium and clinical status recommended.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Continuous infusion of magnesium sulfate in pregnant women beyond 5-7 days may lead to fetal hypocalcemia, skeletal abnormalities, and osteopenia.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Use with caution in patients with renal impairment due to risk of hypermagnesemia. Monitor serum magnesium, respiratory rate, deep tendon reflexes, and urine output during continuous administration. May cause hypotension, respiratory depression, and cardiac arrest in overdose.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to magnesium or any component of the formulation. Heart block or myocardial damage. Severe renal impairment (Cr Cl < 20 m L/min) unless necessary. Preeclampsia/eclampsia with pulmonary edema (relative).
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No significant food interactions. Oral magnesium supplements may be taken with meals to minimize gastrointestinal discomfort. Avoid excessive intake of high-fiber foods, which can reduce magnesium absorption.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
FDA Pregnancy Category D (prolonged use >5-7 days or continuous use near term). First trimester: Limited data; no evidence of major malformations. Second/third trimester: Prolonged use may cause fetal hypocalcemia, skeletal demineralization, and neonatal hypotonia. Use >5-7 days near term increases risk of neonatal hypermagnesemia (respiratory depression, hypotonia). Transient fetal bradycardia may occur during IV administration.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Magnesium sulfate is excreted into breast milk; M/P ratio approximately 0.5-0.8. Milk levels are 10-30% of maternal serum levels. Generally considered compatible with breastfeeding due to rapid neonatal renal clearance. Monitor infant for hypotonia, sedation, or feeding difficulties, especially in preterm or renal-impaired infants.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No routine dose adjustment required in pregnancy due to pharmacokinetic changes; however, loading dose (e.g., 4-6 g IV) followed by maintenance (1-2 g/hour) is standard. Maintain serum magnesium 4-7 m Eq/L. In renal impairment, reduce maintenance dose by 50-75% and monitor levels closely. Postpartum: no adjustment needed.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Monitor deep tendon reflexes, respiratory rate, and urine output during IV infusion. Have calcium gluconate ready to reverse magnesium toxicity. In preeclampsia/eclampsia, administer IV loading dose of 4-6 g followed by 1-2 g/hour. Do not exceed 5 g IM per injection site. Use with caution in renal impairment; reduce dose if creatinine clearance <30 m L/min. Check serum magnesium levels if toxicity suspected. Avoid concurrent use with CNS depressants.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Report symptoms of magnesium toxicity such as muscle weakness, slowed breathing, or lightheadedness.,Do not drive or operate heavy machinery until you know how magnesium sulfate affects you.,Take oral magnesium supplements with food to reduce stomach upset.,Inform your doctor if you have kidney problems or are taking other medications.,During infusion, you may feel warmth, flushing, or sweating.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Felbamate, an antiepileptic drug, potentiates the central nervous system (CNS) depressant effects of magnesium sulfate, a tocolytic and anticonvulsant agent. This additive pharmacodynamic interaction can lead to excessive sedation, respiratory depression, and impaired motor coordination. Clinically, concurrent use may exacerbate hypotonia, hyporeflexia, and somnolence, particularly in patients with renal impairment or those receiving high doses."
"Coadministration of Clevidipine, a dihydropyridine calcium channel blocker, and Magnesium sulfate, which acts as a physiological calcium antagonist, potentiates the hypotensive and negative inotropic effects due to additive inhibition of calcium influx into cardiac and vascular smooth muscle cells. This can lead to exaggerated reductions in blood pressure, bradycardia, and impaired cardiac contractility, particularly in patients with pre-existing cardiovascular compromise. Severe hypotension and heart block have been reported, especially during intravenous administration of both agents."
"The combination of nicardipine, a calcium channel blocker, and magnesium sulfate, a calcium antagonist, synergistically reduces vascular smooth muscle contractility and myocardial conduction. This additive pharmacodynamic effect can lead to profound hypotension, bradycardia, and impaired cardiac contractility, particularly in patients with pre-existing cardiovascular compromise. Clinically, patients may experience symptomatic hypotension, dizziness, or syncope, and in severe cases, cardiovascular collapse may occur."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAGNESIUM SULFATE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
MAGNESIUM SULFATE is a Electrolyte that works by Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAGNESIUM SULFATE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAGNESIUM SULFATE is: IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAGNESIUM SULFATE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAGNESIUM SULFATE is classified as Category C. FDA Pregnancy Category D (prolonged use >5-7 days or continuous use near term). First trimester: Limited data; no evidence of major malformations. Second/third trimester: Prolonged. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.